FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.96 USD
0 (0%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
15.3B
18.88B
22.24B
25.1B
28.17B
32.83B
38.27B
44.61B
52B
60.62B
Revenue %
-
23.42
17.76
12.87
12.23
16.57
16.57
16.57
16.57
Operating Cash Flow
7.22B
9.46B
11.2B
11.98B
14.78B
16.28B
18.97B
22.12B
25.78B
30.05B
Operating Cash Flow %
47.21
50.11
50.34
47.73
52.47
49.57
49.57
49.57
49.57
Cap Ex
-708M
-814M
-1.1B
-371M
-474M
-1.12B
-1.3B
-1.52B
-1.77B
-2.06B
Cap Ex %
-4.63
-4.31
-4.93
-1.48
-1.68
-3.41
-3.41
-3.41
-3.41
Free Cash Flow
6.52B
8.65B
10.1B
11.61B
14.31B
15.16B
17.67B
20.6B
24.01B
27.99B
